文献速递浆细胞疾病

游离轻链负荷对硼替佐米方案治疗的AL淀粉样变性患者的预测价值

Predictive value of free light chain burden in patients with AL amyloidosis treated with bortezomib-based regimens.
PubMed 文献 · Blood Adv · 2025-01-01

本研究为回顾性多中心研究,纳入223例新诊断AL淀粉样变性患者,接受CyBorD或DaraCyBorD治疗。研究发现,基线dFLC>180 mg/L在硼替佐米/达雷妥尤单抗时代不再具有预后价值,并对2012 Mayo分期系统的效用提出质疑。

要点

  • 基线dFLC>180 mg/L在CyBorD/DaraCyBorD治疗时代不再预测不良预后。
  • 研究纳入223例新诊断AL淀粉样变性患者,接受CyBorD或DaraCyBorD治疗。
  • 2012 Mayo分期系统在高效化疗免疫治疗时代的效用受到质疑。

核心结论

  • 在CyBorD/DaraCyBorD治疗AL淀粉样变性的时代,dFLC>180 mg/L不再具有预后价值,并对2012 Mayo分期系统的效用提出质疑。

研究设计与样本

  • 回顾性多中心研究,纳入223例新诊断AL淀粉样变性患者,接受CyBorD或DaraCyBorD治疗。

主要发现

  • 研究分析了基线受累FLC与治疗开始后28天及3、6、9、12个月血液学缓解的关联。
  • 研究比较了基线dFLC低(<180 mg/L)、中(180-400 mg/L)、高(>400 mg/L)患者的OS。
  • 研究评估了骨髓浆细胞负荷对CyBorD或DaraCyBorD治疗缓解和OS的预后价值。
  • 研究评估了2012 Mayo分期系统在CyBorD和DaraCyBorD队列中的预后价值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A difference between involved and uninvolved free light chains (dFLC) ≥180 mg/L is part of the 2012 Mayo staging system for amyloid light chain (AL) amyloidosis given its negative impact on overall survival (OS). However, none of the 758 patients evaluated to develop and validate this staging system received bortezomib or daratumumab-containing regimens. Over the past 2 decades, cyclophosphamide-bortezomib-dexamethasone (CyBorD) and, more recently, daratumumab-CyBorD (DaraCyBorD) have become cornerstone treatments for AL amyloidosis, demonstrating high efficacy in rapidly normalizing FLC levels. We hypothesized that, in patients with newly diagnosed AL amyloidosis treated with bortezomib- and daratumumab-based regimens, a baseline high FLC burden may no longer predict adverse prognosis. In this retrospective, multicenter study of 223 patients with newly diagnosed AL amyloidosis treated with CyBorD or DaraCyBorD therapy, we investigated (1) the association between baseline involved FLC and dFLC hematologic response at 28 days and 3, 6, 9, and 12 months after the commencement of therapy; (2) the OS of patients with baseline low (<180 mg/L), medium (180-400 mg/L), and high (>400 mg/L) dFLC; and (3) the prognostic value of bone marrow plasma cell burden in determining response to CyBorD or DaraCyBorD therapy and OS and, finally, the prognostic value of the 2012 Mayo staging system in the CyBorD and DaraCyBorD cohorts. Our findings suggest that a dFLC of >180 mg/L no longer holds prognostic value in the era of CyBorD/DaraCyBorD-based AL amyloidosis therapy and question the utility of the Mayo 2012 staging system in the era of highly effective chemoimmunotherapies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Saunders B, Theodorakakou F, Fotiou D, et al. Predictive value of free light chain burden in patients with AL amyloidosis treated with bortezomib-based regimens. Blood Adv. 2025. PMID: 40305663. doi:10.1182/bloodadvances.2024015528

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。